首页> 外文期刊>Bone marrow transplantation >The stem cell transplant program in Pakistan--the first decade.
【24h】

The stem cell transplant program in Pakistan--the first decade.

机译:巴基斯坦的干细胞移植计划-第一个十年。

获取原文
获取原文并翻译 | 示例
       

摘要

Stem cell transplantation is curative in a number of otherwise fatal hematological diseases. In Pakistan, SCT was started in October 1995 at Dr Ziauddin Hospital by Dr Tahir Shamsi and his team. The first case was of a young man suffering from AML. In 1999, allogeneic BMT was started at Bismillah Taqee Institute of Health Sciences and Blood Diseases Centre, Karachi. In 2001, the Armed Forces Bone Marrow Transplant Centre, started functioning. Since then, over 350 allogeneic stem cell transplants have been carried out in these latter two centers. Another 50 autologous procedures were carried out in all centers. In 2004, a third center started transplants at the Aga Khan Hospital. The main indications for transplant are aplastic anemia, beta-thalassemia major and hematological malignancies. HLA-identical sibling donors provide stem cells for the recipient. In 70% of cases, a matched donor is identified. In sharp contrast to the rest of the world, the majority of transplants are allogeneic, donor-recipient pairs are CMV positive and fungal infection, tuberculosis and malaria are particular problems. The early results are promising, with transplant-related mortality reported to be 10-20%, whereas long-term survival is reported to be 78, 72 and 49% in aplastic anemia, beta-thalassemia major and leukemia, respectively. Financial constraints, poor socioeconomic status, poor transfusion services, trained human resources and difficulty in keeping pace with technological advances are major hurdles in the growth of transplant medicine. Government support is badly needed to strengthen existing facilities and to develop more centers.
机译:干细胞移植可以治愈许多其他致命的血液疾病。在巴基斯坦,Tahir Shamsi博士及其团队于1995年10月在Ziauddin医院开始了SCT。第一例是一名年轻人患有反洗钱。 1999年,异基因BMT在卡拉奇的Bismillah Taqee卫生科学与血液病研究所开始。 2001年,武装部队骨髓移植中心开始运作。自那时以来,在后两个中心进行了350多次同种异体干细胞移植。在所有中心又进行了50次自体手术。 2004年,第三个中心在阿迦汗医院开始了移植手术。移植的主要指征是再生障碍性贫血,重型β地中海贫血和血液系统恶性肿瘤。与HLA相同的同胞供体为受体提供干细胞。在70%的情况下,可以找到匹配的捐助者。与世界其他地区形成鲜明对比的是,大多数移植是同种异体移植,供体-受体对是CMV阳性,真菌感染,结核病和疟疾是特别的问题。早期结果令人鼓舞,据报道与移植相关的死亡率为10-20%,而再生障碍性贫血,重型β地中海贫血和白血病的长期存活率据报道分别为78%,72%和49%。财政拮据,不良的社会经济地位,不良的输血服务,训练有素的人力资源以及难以跟上技术进步是移植医学发展的主要障碍。迫切需要政府的支持来加强现有设施和发展更多的中心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号